Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination.

Figure 1 D shows the differences between the 2 mRNA vaccines among patients receiving anti-TNF-α antagonist monotherapy, with graphical evidence of greater decay in BNT162b2 (n = 25; EDC 2.4%/day; P = .002; half-life, 28 days) compared with mRNA-1273 (n = 10; EDC 0.9%/day; P = .188; half-life, 76 days), and slope difference approaching significance ( P = .109), despite relatively low sample size.

also in 2,450 other papers